Management Strategies for Hepatotoxicity Associated With Elexacaftor/Tezacaftor/Ivacaftor: Results of a Provider Survey
Clinical practices regarding LFT monitoring and ETI dose adjustments in relation to hepatotoxicity and LFT abnormalities in PwCF with and without baseline CFLD or elevations in LFTs across adult and pediatric CF Foundation accredited care centers and affiliate programs in the United States are described.